Gossamer Bio Inc. (GOSS)
10.20
-0.50 (4.67%)
Upcoming Events
Latest Headlines
Form 8-K Gossamer Bio, Inc. For: Sep 10
September 11, 2026 8:02 AM - SEC Filing
Gossamer Bio completes 1-for-80 reverse stock split on Nasdaq
September 11, 2026 8:00 AM - StreetInsider
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
September 11, 2026 8:00 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
August 27, 2026 7:09 AM - StreetInsider
Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Christian Waage
August 26, 2026 6:13 PM - SEC Filing
Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Peterson Caryn
August 26, 2026 6:13 PM - SEC Filing
Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Smith Robert Paul JR
August 26, 2026 6:12 PM - SEC Filing
Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Giraudo Bryan
August 26, 2026 6:10 PM - SEC Filing
Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Hasnain Faheem
August 26, 2026 6:08 PM - SEC Filing
Form 8-K Gossamer Bio, Inc. For: Aug 24
August 26, 2026 4:02 PM - SEC Filing
Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.
August 24, 2026 8:12 PM - SEC Filing
Form 8-K Gossamer Bio, Inc. For: Aug 20
August 21, 2026 8:01 AM - SEC Filing
Gossamer Bio raises up to $250M in private placement for PAH drug
August 21, 2026 8:00 AM - StreetInsider
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
August 21, 2026 8:00 AM - BizWire
Gossamer Bio Inc. (GOSS) PT Lowered to $4 at Piper Sandler
August 14, 2026 8:26 AM - StreetInsider
Gossamer Bio Inc. (GOSS) Tops Q2 EPS by 4c
August 13, 2026 4:03 PM - StreetInsider
Form 8-K Gossamer Bio, Inc. For: Aug 13
August 13, 2026 4:03 PM - SEC Filing
Form 10-Q Gossamer Bio, Inc. For: Jun 30
August 13, 2026 4:02 PM - SEC Filing
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026 4:01 PM - BizWire
Form SCHEDULE 13G Gossamer Bio, Inc. Filed by: Opaleye Management Inc.
July 29, 2026 4:06 PM - SEC Filing
Form SCHEDULE 13G/A Gossamer Bio, Inc. Filed by: BlackRock, Inc.
July 29, 2026 3:21 PM - SEC Filing
Leerink Upgrades Gossamer Bio Inc. (GOSS) to Outperform
July 28, 2026 2:36 AM - StreetInsider
Form 8-K Gossamer Bio, Inc. For: Jul 23
July 27, 2026 4:01 PM - SEC Filing
Gossamer Bio plans NDA submission for seralutinib in September 2026
July 27, 2026 7:02 AM - StreetInsider
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
July 27, 2026 7:00 AM - BizWire
Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.
July 24, 2026 9:15 PM - SEC Filing
Form 8-K Gossamer Bio, Inc. For: Jul 14
July 15, 2026 6:18 AM - SEC Filing
Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.
July 1, 2026 9:24 PM - SEC Filing
Gossamer Bio sets conversion rate for 2030 convertible notes
July 1, 2026 9:03 AM - StreetInsider
Form 8-K Gossamer Bio, Inc. For: Jul 01
July 1, 2026 9:01 AM - SEC Filing
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
July 1, 2026 9:00 AM - BizWire
Gossamer Bio Inc. (GOSS) PT Lowered to $2 at H.C. Wainwright
June 26, 2026 6:40 AM - StreetInsider
Form 8-K Gossamer Bio, Inc. For: Jun 17
June 17, 2026 8:01 AM - SEC Filing
Gossamer Bio exchange offer closes with $18.9M in notes remaining
June 17, 2026 8:01 AM - StreetInsider
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
June 17, 2026 8:00 AM - BizWire
Full Article List
